ライフサイエンスコーパス: bispecific

1 ng the reactivity patterns of pHLA-targeting bispecifics.

2 e CD5xDR-CR3 or -MUT4 background, leading to bispecific Ab (BsAbs) with a more rigid or flexible stru

3 Bispecific Abs (BsAbs) are an emerging cancer immunother

4 We also engineered bispecific Abs (bsAbs) that bound tetravalently by utili

5 T4, were designed and tested, and prototypic bispecific Abs directed against CD5 and HLA-DR were prod

6 system, such as Abs with effector functions, bispecific Abs, and checkpoint inhibitors, many small mo

7 production of tetravalent IgG1-like chimeric bispecific Abs.

8 With the introduction of emicizumab, the bispecific ACE910 antibody, as a non-FVIII alternative t

9 cell potency, we conclude that proper use of bispecific adapters could potentially avoid a life-threa

10 A cocktail of tumor-targeted bispecific adapters greatly augments CAR T-cell therapie

11 uggest that a carefully designed cocktail of bispecific adapters in combination with antifluorescein

12 utilized a cocktail of low-molecular-weight bispecific adapters, each comprised of fluorescein linke

13 cal detection by fabricating a high-affinity bispecific AEC (bsAEC) using two Catcher/Tag systems.

14 ndogenous biotin interference, make the CD38 bispecific an attractive candidate for clinical translat

15 ein we describe CLDN18.2-targeting via a CD3-bispecific and an antibody drug conjugate and the charac

16 Anti-hCLDN18.2 ADC, CD3-bispecific and diabody, targeting a protein sequence con

17 igen receptor-expressing NK cells (CAR-NKs), bispecific and trispecific killer cell engagers (BiKEs a

18 limitation through a first-in-human trial of bispecific anti-CD20, anti-CD19 (LV20.19) CAR T cells fo

19 in their report from a phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13.

20 We further demonstrate that a bispecific anti-CD70/SIRPalpha antibody outperforms indi

21 Here, we report the development of bispecific anti-Env neutralizing antibodies (biNAbs) wit

22 Here we show that the bispecific anti-FGFR1/KLB agonist antibody BFKB8488A ind

23 Chemically programmed bispecific antibodies (biAbs) endow target cell-binding

24 e used antibody engineering to develop novel bispecific antibodies (Bis-mAbs) that are cross-reactive

25 e observed for the expression of therapeutic bispecific antibodies (BisAbs) is high product aggregate

26 ied using PrA-MS and are presented here: (a) bispecific antibodies (bsAb) and (b) glycan engineered a

27 Methods to rapidly generate high quality bispecific antibodies (BsAb) having normal half-lives ar

28 T cell-recruiting bispecific antibodies (bsAb) show promise in hematologic

29 Bispecific antibodies (bsAb) that bridge tumor cells and

30 d DNL to generate a novel class of trivalent bispecific antibodies (bsAb), each comprising an anti-CD

31 for the generation of therapeutic human IgG1 bispecific antibodies (bsAb).

32 Bispecific antibodies (bsAbs) and antibody-drug conjugat

33 Bispecific antibodies (bsAbs) are Abs composed of two di

34 Bispecific antibodies (bsAbs) are of significant importa

35 Bispecific antibodies (bsAbs) are one of the most versat

36 Bispecific antibodies (bsAbs) combine the antigen specif

37 Many methods have been developed to produce bispecific antibodies (BsAbs) for industrial application

38 Bispecific antibodies (BsAbs) have drawn increasing inte

39 Generation of bispecific antibodies (BsAbs) having two unique Fab doma

40 cacy of engaging multiple drug targets using bispecific antibodies (BsAbs) is affected by the relativ

41 g T cells to hematological malignancies with bispecific antibodies (BsAbs) is an attractive strategy.

42 Producing pure and well behaved bispecific antibodies (bsAbs) on a large scale for precl

43 Four different formats of bispecific antibodies (bsAbs) were generated that consis

44 This results in functionally monovalent, bispecific antibodies (bsAbs) with unknown specificity a

45 Bispecific antibodies (BsAbs), with a unique mechanism o

46 T-cell bispecific antibodies (TCBs) crosslink tumor and T-cells

47 T-cell-dependent bispecific antibodies (TDBs) are promising cancer immuno

48 Synergistic bispecific antibodies against HIV exhibit extraordinary

49 ntibody-drug conjugates, conjugate vaccines, bispecific antibodies and cell therapy.

50 disulfide bonds in both half antibodies and bispecific antibodies and identifying cysteine-related m

51 throughput analyses of antibodies, including bispecific antibodies and potential mispaired side produ

52 Bispecific antibodies are asymmetrical compared to their

53 Bispecific antibodies are considered attractive bio-ther

54 These results suggest that IgG-based bispecific antibodies are promising candidates for the p

55 Bispecific antibodies are regarded as the next generatio

56 be the creation and production of plant-made bispecific antibodies based on trastuzumab and pertuzuma

57 hole approach is an effective way to produce bispecific antibodies by driving heterodimerization with

58 icient heavy-chain assembly of heterodimeric bispecific antibodies by exchanging the interdomain prot

59 Bispecific antibodies combine two different antigen-bind

60 All 3 bispecific antibodies exhibited identical pharmacokineti

61 tional monoclonal antibodies, knob-into-hole bispecific antibodies face unique challenges in producti

62 ath to generating highly effector-attenuated bispecific antibodies for preclinical studies.

63 These findings support the use of bispecific antibodies for the prevention or treatment of

64 ong implications for the design of efficient bispecific antibodies for therapeutic applications.

65 The present review discusses novel bispecific antibodies for TNBC and emerging TNBC targets

66 Bispecific antibodies have great potential to be the nex

67 orm conventional monoclonal antibodies, many bispecific antibodies have issues regarding production,

68 Such "Trojan horse" bispecific antibodies have potential as broad antifilovi

69 Bispecific antibodies have received wide attention as pr

70 These bispecific antibodies hold promise as novel prophylactic

71 In this study, we characterized bispecific antibodies in which a BBB-crossing antibody f

72 g, this mechanism leads to the production of bispecific antibodies in which the LAIR1 domain is preci

73 T-cell-directed killing of tumor cells using bispecific antibodies is a promising approach for the tr

74 However, analysis of bispecific antibodies is challenging because multiple fo

75 usion proteins, antibody-drug conjugates, or bispecific antibodies may undergo biotransformation (suc

76 Using bispecific antibodies of different valencies to cell sur

77 Emerging bispecific antibodies offer the potential for even bette

78 sent an opportunity for approaches utilizing bispecific antibodies or chimeric antigen receptor T cel

79 Most analyses of bispecific antibodies rely on liquid chromatography with

80 Bispecific antibodies show great promise as intrinsic co

81 Here, we report engineered bispecific antibodies that are the most potent and broad

82 Recently, bispecific antibodies that redirect the cytotoxic activi

83 e, we describe a new approach for generating bispecific antibodies using a common light chain format

84 e efficient heterodimerization, resulting in bispecific antibodies with physiochemical properties ver

85 Fc containing therapeutics (e.g. antibodies, bispecific antibodies, and Fc fusions) requiring lack of

86 overed such as monoclonal antibodies (mAbs), bispecific antibodies, antibody drug conjugates (ADCs),

87 Bispecific antibodies, but not parent mAbs, neutralized

88 egies predicated on streptavidin and biotin, bispecific antibodies, complementary oligonucleotides, a

89 increasing number of multivalent antibodies, bispecific antibodies, fusion proteins, and targeted nan

90 eting" methods, particularly those utilizing bispecific antibodies, have greatly enhanced the therape

91 l binding scaffolds, activatable antibodies, bispecific antibodies, immunocytokines, antibody-drug co

92 Bispecific antibodies, including bispecific IgG, show so

93 otein interface design to create therapeutic bispecific antibodies, the engineering of light-inducibl

94 For bispecific antibodies, the ratio of the expression level

95 ery with possible functional implications in bispecific antibodies.

96 tent antibodies and explore the potential of bispecific antibodies.

97 as with chimeric antigen receptor T cells or bispecific antibodies.

98 o 20-fold more potently than a CS1-targeting bispecific antibody (BiFab-CS1) developed in an analogou

99 ation of homodimer impurities in therapeutic bispecific antibody (bsAb) drug products is essential to

100 The term bispecific antibody (bsAb) is used to describe a large f

101 inical evaluation of a recombinant AC133xCD3 bispecific antibody (bsAb) that redirects human polyclon

102 Among these, a Her2 x CD3 bispecific antibody (BsAb) was constructed by inserting

103 chimeric anticarcinoembryonic antigen (CEA) bispecific antibody (BsMAb) and peptides labeled with (1

104 To counter this problem, we developed a bispecific antibody (FIT-1) comprising ZKA190 and a seco

105 The anti-FcRH5/CD3 T cell-dependent bispecific antibody (TDB) targets the B cell lineage mar

106 NA to reduce antithrombin expression and the bispecific antibody ACE910/emicizumab.

107 The CD30/CD16A-bispecific antibody AFM13 is an innate immune cell engag

108 We report a bispecific antibody against B cell maturation antigen (B

109 ased on a glycoprotein A33 (GPA33)-targeting bispecific antibody and a small-molecule radioactive hap

110 pecific therapeutics, including immunotoxin, bispecific antibody and chimeric antigen receptor T cell

111 Psl, and susceptibility to the anti-PcrV/Psl bispecific antibody and clinical candidate MEDI3902.

112 undergo in vivo Fab arm exchange leading to bispecific antibody and off-target effects.

113 position of the blood-brain barrier-crossing bispecific antibody antagonist of metabotropic glutamate

114 otein-coupled receptors using a BBB-crossing bispecific antibody approach and emerging principles tha

115 However, FVIII and the bispecific antibody are fundamentally different proteins

116 rm of generating bispecific IgG antibodies, "Bispecific Antibody by Protein Trans-splicing (BAPTS)".

117 en with the addition of novel monoclonal and bispecific antibody constructs targeting CD19 and CD22 m

118 or TNBC and emerging TNBC targets for future bispecific antibody development.

119 This bispecific antibody efficiently induces targeted cell ly

120 The bispecific antibody emicizumab is increasingly used for

121 the construction of other disease-targeting bispecific antibody fragments for early detection and di

122 c potential of T cells engaged by a BCMAxCD3-bispecific antibody increased notably with the depletion

123 Using the DEKK format, we generated the bispecific antibody MCLA-128, targeting human EGF recept

124 Comparisons between two versions of the bispecific antibody molecule and analysis of stressed sa

125 We developed a modular bispecific antibody platform that directs the complement

126 A BCMA-targeted bispecific antibody presents a promising treatment optio

127 e dramatically improved therapeutic index of bispecific antibody pretargeting appears to be sufficien

128 ability, enabling efficient knobs-into-holes bispecific antibody production and a robust path to gene

129 lection of clones with the highest purity of bispecific antibody production and the results significa

130 Emicizumab is a bispecific antibody recognizing both the enzyme factor I

131 o half antibodies to form the knob-into-hole bispecific antibody requires an additional in vitro asse

132 ing distinct facets of fracture healing, the bispecific antibody shows superior bone repair activity

133 ed safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2 and vascula

134 ErbB3 ligands is blocked by the tetravalent bispecific antibody targeting IGF-1R and ErbB3, istiratu

135 Emicizumab, a bispecific antibody that acts as a substitutive therapy

136 pretargeting" approach through engineering a bispecific antibody that binds both cell-surface ICAM-1

137 eloid-Specific TNF Inhibitor)--a recombinant bispecific antibody that binds to the F4/80 surface mole

138 A bispecific antibody that has two different antibody bind

139 by this prediction, we engineered MM-131, a bispecific antibody that is monovalent for both Met and

140 ells and describe JNJ-64407564, a GPRC5DxCD3 bispecific antibody that recruits CD3+ T cells to GPRC5D

141 oint inhibitors, adoptive cell transfer, and bispecific antibody therapy.

142 Here, we engineered a bispecific antibody to detect K11/K48-linked chains and

143 variant generated during the production of a bispecific antibody using the knob-into-hole heterodimer

144 The digestion of a bispecific antibody with competitive inhibition of asper

145 ases bone mass, we engineer a first-in-class bispecific antibody with single residue pair mutations i

146 One bispecific antibody, 10E8V2.0/iMab, neutralized 118 HIV-

147 usion: Immuno-PET using anti-CEA/anti-IMP288 bispecific antibody, followed by (68)Ga-IMP288, is a pot

148 d, following conversion to a T cell-engaging bispecific antibody, has potent cytotoxicity toward ROR2

149 We also demonstrate that a bispecific antibody, targeting a c-Myc tag on CAR T cell

150 Bispecific antibody-based therapeutics for the treatment

151 Abs with the potency of cytotoxic agents via bispecific antibody-toxin conjugation.

152 e-related variants in an IgG1 knob-into-hole bispecific antibody.

153 nity Re-Targeting (DART) proteins, which are bispecific, antibody-based molecules that can bind 2 dis

154 Here, we describe a bispecific-antibody strategy to target this interaction,

155 r initial targeting of a trivalent anti-CEA, bispecific, antipeptide antibody.

156 The bispecific binding modality was generated by molecular c

157 Furthermore, the bispecific binding protein successfully interferes with

158 To overcome this issue, we generated a bispecific/biparatopic antibody (BiSAb) that targets two

159 ods of SHIV infection, we used LSEVh-LS-F, a bispecific bnAb targeting the CD4 binding site and CD4-i

160 These TCR/CD3 bispecifics can redirect T cells to kill tumor cells wit

161 We describe a novel bispecific CAR in which a CD4 segment is linked to a sin

162 ens on glioblastomas, we hypothesized that a bispecific CAR molecule would mitigate antigen escape an

163 Taken together, the BCMA/CS1 bispecific CAR presents a promising treatment approach t

164 We demonstrate that BCMA/CS1 bispecific CAR-T cells exhibit superior CAR expression a

165 port the rational design and optimization of bispecific CAR-T cells with robust activity against hete

166 but also can be used to create single-chain bispecific CARs and TCRs.

167 Bispecific CARs may improve clinical responses by mitiga

168 The bispecific CD19-directed CD3 T-cell engager, blinatumoma

169 ed that single-chain variable fragment-based bispecific chemically self-assembled nanorings (CSANs) c

170 This new class of bispecific compounds may be especially important as a th

171 We show that a bispecific conjugate that binds both CD3 and CD123 elimi

172 MM and non-Hodgkin lymphoma (NHL), the CD38-bispecific construct demonstrated excellent blood cleara

173 The bispecific constructs were all able to bind both target

174 r extensive biodistribution studies of novel bispecific constructs, as the results might have implica

175 bispecific variants, but not their bivalent bispecific counterparts, mediated a greater degree of tu

176 roved with the adjuvant use of a VEGF-A/Ang2-bispecific CovX-body (CVX-241) but not when CVX-060 is c

177 ur results demonstrate that antiCD3/antiCD22 bispecific CSANs offer a potential alternative to CARs,

178 The described bispecific DARPin protein has the ability to co-ligate F

179 ize both motifs, but the molecular basis for bispecific DNA recognition is not understood.

180 (Hc) heterodimers represent a major class of bispecific drug candidates.

181 -MET with potentially broad implications for bispecific drug efficacy and design.

182 Systemic administration of the bispecific DVD-Ig or the TGF-beta mAb (1-10 mg/kg) but n

183 Affinity-attenuated bispecific EGFR x c-MET antibody-drug conjugates demonst

184 We engineered a bispecific EGFR-cMet antibody (JNJ-61186372) with multip

185 human T-cell receptor, a technology known as bispecific engagement by antibodies based on the T-cell

186 l antibodies and combined them into a single bispecific Fc fusion protein (the Fc dual-affinity retar

187 anti-H5N1 influenza virus antibodies into a bispecific FcDART molecule, which represents a strategy

188 Bispecific forkhead proteins recognize both motifs, but

189 We demonstrate that the multivalent and bispecific format allows the antiCD3/antiCD22 CSANs to s

190 ribution experiments comparing SA-biotin and bispecific FP (2H7-Fc-C825) PRIT in murine subjects bear

191 In this study, we engineered a bispecific fusion protein (FP) that evades the limitatio

192 This bispecific fusion protein redirects T cells to specifica

193 nancies, for which we developed an anti-CD38-bispecific fusion protein that eliminates endogenous bio

194 imer under different storage conditions, the bispecific heterodimer, guided by the knob-into-hole ass

195 ine the affinity of parental (homodimer) and bispecific (heterodimer) interactions within the CH3 dom

196 escribe a new strategy for making monovalent bispecific heterodimeric IgG antibodies in mammalian cel

197 In addition, the bispecific heterodimeric IgG derived from anti-HER2 and

198 enhancement could be embedded in monovalent bispecific heterodimeric IgG to make best-in-class thera

199 ncy reversal with AZD5582 and clearance with bispecific HIVxCD3 DART molecules in SHIV.C.CH505-infect

200 Here, we combined AZD5582 with bispecific HIVxCD3 DART molecules to determine the impac

201 This bispecific IgG also demonstrated in vivo pharmacokinetic

202 a generic technology platform of generating bispecific IgG antibodies, "Bispecific Antibody by Prote

203 heavy chain pairing variants in a mixture of bispecific IgG assembled in vivo upon coexpression down

204 Generating bispecific IgG by coexpression of two different light an

205 Bispecific IgG can be made by separate expression and pu

206 ttering (MALS) to analyze different forms of bispecific IgG molecules under native conditions.

207 We developed four different bispecific IgG variants that included antibodies targeti

208 contribution of doubly light chain mispaired bispecific IgG was demonstrated.

209 Using an anti-IL-4/IL-13 bispecific IgG, a mass spectrometric characterization me

210 Bispecific antibodies, including bispecific IgG, show some promise in clinical trials as

211 h factor receptor (EGFR) on tumor cells in a bispecific IgG-like format based on affinity-optimized v

212 -cell solution for streamlined production of bispecific IgG.

213 aired IgG species in addition to the desired bispecific IgG.

214 nt human IgG clones, including a non-natural bispecific IgG1 candidate, targeting Pseudomonas aerugin

215 fically, a series of monovalent and bivalent bispecific IgGs composed of the anti-HER2 trastuzumab mo

216 We show that these bispecific IgGs display features of both antibody specif

217 Among the bispecific IgGs tested, VRC07 x PG9-16 displayed the mos

218 ed constructs (including Fab, Fc-fusions and bispecifics) in mammalian cells.

219 erefore, we evaluated an antibody-engineered bispecific inhibitor against TAFI and PAI-1 (heterodimer

220 In conclusion, administration of a bispecific inhibitor against TAFI and PAI-1 results in a

221 ex is linked to the actin cytoskeleton via a bispecific interaction with an exon 17b-encoded peptide.

222 ontrols, suggesting target engagement of TfR bispecific is not limited.

223 Bispecific killer cells engagers (BiKEs) which can bind

224 A bispecific mAb targeting both Psl and PcrV enhanced neut

225 icate that targeting CLDN18.2 with an ADC or bispecific modality could be a valid therapeutic approac

226 inders against FcgammaRIIB and to generate a bispecific molecule simultaneously targeting FcgammaRIIB

227 Overall, systemic delivery of a bispecific molecule targeting an extracellular matrix pr

228 anding of both the homodimer variant and the bispecific molecule.

229 rated into a comprehensive panel of distinct bispecific molecules by controlled Fab-arm exchange (Duo

230 Proteolysis targeting chimeras (PROTACs) are bispecific molecules containing a target protein binder

231 Bispecific molecules engineered to present two different

232 like expression and assembly of well-behaved bispecific molecules that combine an anti-CD3 antibody w

233 Soluble bispecific molecules that incorporate an anti-CD3 effect

234 y other methods we tested, isolating desired bispecific molecules, parental homodimers, half molecule

235 g impurities across a broad spectrum of aCD3 bispecific molecules.

236 Further, we found that an Fc-modified, bispecific monoclonal antibody against conserved epitope

237 Blinatumomab, a bispecific monoclonal antibody construct that enables CD

238 PRIT of CEA-expressing xenografts, using the bispecific monoclonal antibody TF2 (anti-CEA x anti-hist

239 b, a subcutaneously administered, humanised, bispecific, monoclonal antibody, is approved to treat pe

240 whereas at 600- and 1000-microCi doses, the bispecific outperformed the SA approach, curing 35% more

241 al proof of concept for the preferred use of bispecific PRIT in future clinical trials, due to a slig

242 In therapy studies, CD38-bispecific PRIT resulted in 100% complete remissions by

243 The high efficacy of bispecific PRIT, combined with its reduced risk of immun

244 significantly benefit many T-cell-recruiting bispecific programs.

245 4/80(-)) emerged in the liver and spleens of bispecific protein-treated mice.

246 nd/or diagnostic agents that can bind to the bispecific proteins accumulated on the surface of target

247 lving the administration of 1) a cocktail of bispecific proteins that can collectively bind to the en

248 In direct comparisons, efficacy of the CD38 bispecific proved equal or superior to streptavidin (SA)

249 We have developed (111)In-labeled bispecific radioimmunoconjugates (bsRICs) that bind HER2

250 We describe herein the identification of bispecific RBP4 antagonist-TTR tetramer kinetic stabiliz

251 tool for generating sandwich ELISA-grade and bispecific reagents.

252 or pharmacological blockade, we engineered a bispecific receptor decoy by attaching the TGF-beta-neut

253 importance of DNA shape in the mechanism of bispecific recognition.

254 d rabbit IgG primary antibodies, whereas the bispecific rILSA, MG1Nb-Nluc-ABD, mutually bound to both

255 An alternative bispecific scaffold (Bipod) comprising an scFv and a Fab

256 ABARAP, GABL1, GABL2, and LC3C, as well as a bispecific sensor for LC3A and LC3B.

257 he pan-HDAC inhibitor, vorinostat, to create bispecific single molecules with both JAK and HDAC targe

258 t surface antigens pretreated with different bispecific streptavidin-scFv fusion proteins.

259 h chimeric antigen receptor (CAR) T cells or bispecific T cell engager (BiTE) antibodies display seve

260 AMG 110, a bispecific T cell engager (BiTE) antibody construct, ind

261 In this study, a bispecific T cell engager (BiTE) approach was used to di

262 evaluate tumor and tissue uptake kinetics of bispecific T cell engager antibody constructs in preclin

263 findings reveal that T cell activation by a bispecific T cell engager leads to changes in the host m

264 cond and fourth injections of an NK Group 2D bispecific T cell engager protein.

265 previously established for the FDA-approved bispecific T cell engager, blinatumomab, for acute lymph

266 unocompetent mouse tumor model that exhibits bispecific T cell engager-induced toxicity and recapitul

267 Bispecific T cell engagers have demonstrated clinical ef

268 Bispecific T-cell engager (BiTE((R))) antibody construct

269 a glioblastoma-specific tumor antigen, and a bispecific T-cell engager (BiTE) against EGFR, an antige

270 Here we describe a bispecific T-cell engager (BiTE) antibody derived from a

271 Blinatumomab, a bispecific T-cell engager (BiTE) associated with improve

272 L relapses after treatment with the CD19/CD3 bispecific T-cell engager (BiTE) blinatumomab.

273 Blinatumomab, a CD19/CD3-bispecific T-cell engager (BiTE) immuno-oncology therapy

274 Bispecific T-cell engager (BiTE) molecules are designed

275 ally CMV-reactive effector T cells whereas a bispecific T-cell engager activated both effector and re

276 Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting C

277 Blinatumomab is a bispecific T-cell engager antibody construct targeting C

278 Among these, the bispecific T-cell engager blinatumomab has emerged as th

279 The bispecific T-cell engager blinatumomab targeting CD19 ca

280 By using bispecific T-cell engager technology to assess the cytot

281 Blinatumomab is a CD19/CD3 BiTE (bispecific T-cell engager) antibody construct for the tr

282 antigen receptors (CARs) or the infusion of bispecific T-cell engagers (BITEs) have shown antitumor

283 either cell-based (CAR-T) or protein-based (bispecific T-cell engagers) therapies to target cancer c

284 (ii) engineered monoclonal antibodies called bispecific T-cell engagers; (iii) monoclonal antibodies

285 Blinatumomab, a bispecific T-cell engaging antibody construct, transient

286 oncolytic adenoviruses that were armed with bispecific T-cell-engager (BiTE) antibodies.

287 cells, we considered CD43s as a target for a bispecific T-cell-engaging antibody (bTCE) and generated

288 ostat (2), leading to new molecules that are bispecific targeted JAK/HDAC inhibitors.

289 ing single-agent treatment with FOLR1-T-cell bispecific (TCB) antibody and combination therapy of CEA

290 netics, and safety of a CD3 T cell-dependent bispecific (TDB) full-length human IgG1 therapeutic anti

291 ize TGF-beta After systemic injection of the bispecific TGF-beta + FnEDA DVD-Ig or an FnEDA mAb, chem

292 roteins are key potential building blocks of bispecific therapeutic antibodies, but they often suffer

293 postproduction method for the generation of bispecific therapeutic IgGs of which several have progre

294 erlooked when developing clinically relevant bispecific therapeutics.

295 (Sso-KARI) is unusual in being a dodecamer, bispecific to NADH and NADPH, and losing activity above

296 cer therapy have examined the improvement of bispecific trastuzumab/pertuzumab antibodies interacting

297 Affinity-reduced monovalent bispecific variants, but not their bivalent bispecific c

298 antibodies (anti-transferrin receptor [TfR] bispecific versus control antibody) in mouse models of A

299 ver, the mechanisms by which these so-called bispecific VHH heterodimers promote toxin neutralization

300 Finally, a bispecific VNA (VHH-based neutralizing agent) consisting